Statement: the primary trial has a topical intervention, whereas the secondary trial has both oral and IV interventions.
Primary_evidence: INTERVENTION 1:    Mometasone   Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy. INTERVENTION 2:    Placebo   Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm A.
Secondary_evidence: INTERVENTION 1:    Afatinib Monotherapy   Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal. Patients could have dose reduced if 40 mg was not tolerated. INTERVENTION 2:    Afatinib and Paclitaxel or Vinorelbine Combination Therapy   Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy